Daily Cardiology Research Analysis
Three impactful cardiology studies span acute heart failure pharmacotherapy, structural intervention outcomes, and decongestion strategy. A double-blind RCT shows istaroxime improves blood pressure, cardiac output, and wedge pressure without arrhythmic penalty in pre-cardiogenic shock. A meta-analysis of randomized trials confirms TEER lowers heart failure hospitalizations and cardiovascular mortality in functional MR, and a mechanistic RCT challenges sodium restriction by showing isotonic salin
Summary
Three impactful cardiology studies span acute heart failure pharmacotherapy, structural intervention outcomes, and decongestion strategy. A double-blind RCT shows istaroxime improves blood pressure, cardiac output, and wedge pressure without arrhythmic penalty in pre-cardiogenic shock. A meta-analysis of randomized trials confirms TEER lowers heart failure hospitalizations and cardiovascular mortality in functional MR, and a mechanistic RCT challenges sodium restriction by showing isotonic saline augments diuresis/natriuresis in acute heart failure.
Research Themes
- Acute heart failure hemodynamic pharmacotherapy
- Transcatheter edge-to-edge repair outcomes in functional MR
- Decongestion strategies and sodium handling in AHF
Selected Articles
1. Safety and efficacy intravenous istaroxime up to 60 hours for patients with pre-cardiogenic shock.
In a double-blind RCT (n=90) of pre-cardiogenic shock due to acute heart failure, intravenous istaroxime (up to 1.0 µg/kg/min for ≤60 h) significantly increased systolic blood pressure and cardiac output and reduced pulmonary capillary wedge pressure versus placebo. Benefits persisted to 60 hours in patients infused ≥48 hours, with reductions in heart rate and no signal for malignant arrhythmias on Holter monitoring.
Impact: Provides randomized, double-blind evidence for a novel inotrope/lusitrope that improves hemodynamics without arrhythmic penalty in early shock. Addresses an unmet need for agents that raise BP and CO while lowering filling pressures.
Clinical Implications: Istaroxime may be considered in monitored pre-cardiogenic shock/acute heart failure settings to stabilize hemodynamics (raise SBP, increase CO, lower PCWP) without increasing malignant arrhythmias, potentially reducing vasopressor exposure. Confirmation in larger, outcomes-driven trials is needed prior to guideline adoption.
Key Findings
- Primary endpoint: 6-hour SBP AUC significantly higher with istaroxime (LS mean difference 25.6 mmHg*hour; p=0.007).
- Cardiac output increased by 0.66 L/min (p=0.017) and PCWP decreased by 3.8 mmHg (p=0.0017) versus placebo.
- Effect durability to 60 hours in those infused ≥48 hours; heart rate decreased and no increase in malignant arrhythmias on Holter.
- Echocardiography showed improvements in E/A, TAPSE, and LA volume at 24 hours; renal function (eGFR) improved up to 72 hours.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with invasive hemodynamic monitoring.
- Multiple objective endpoints (SBP AUC, CO, PCWP, Holter, echocardiography, renal function) supporting internal consistency.
Limitations
- Single study with modest sample size and short-term hemodynamic endpoints rather than hard clinical outcomes.
- Increase in NT-proBNP despite hemodynamic improvements warrants mechanistic clarification.
Future Directions: Phase III multicenter trials powered for mortality, HF hospitalization, and renal outcomes; define optimal dosing/duration and interaction with vasopressors and diuretics.
BACKGROUND AND AIMS: A drug that improves blood pressure and cardiac output (CO) while reducing pulmonary wedge pressure safely is needed for patients with cardiogenic shock (CS) due to acute heart failure (AHF). METHODS: In a randomized, double-blind, placebo-controlled trial, istaroxime 0.5 to 1.5 µg/kg/min for 24-60 hours was administered to 48 patients, and placebo to 42 patients, with pre-CS due to AHF under hemodynamic monitoring. Echocardiographic and Holter monitoring were done in both parts. RESULTS: Patients randomized to istaroxime had a greater increase in systolic blood pressure (SBP) during the first 6 hours (primary endpoint), ls-mean (SE) 62.0 (6.59) mmHghour vs 36.4 (7.11) in the placebo arm (LS mean difference of 25.6 mmHghour, 95% CI 7.2-44.0 mmHg*h, P = 0.007). In patients administered istaroxime for at least 48 hours, SBP increase persisted for 60 hours. Istaroxime led to a greater increase in CO (0.66 L/min, P = 0.017) and decrease in wedge pressure (3.8 mmHg, P = 0.0017). Relative to average baselines of 3.6 L/min for CO and 22.5 mmHg for wedge pressure, this translates into improvements of 18.3% and 16.9%, respectively. Echocardiographic assessments showed improvements in E/A, TAPSE, and LA volume at 24 hours. There were improvements in eGFR at 24-72 hours and NYHA class to 72 hours. NT-proBNP increased more in istaroxime-treated patients. Heart rate decreased more in the first 24 hours in istaroxime-treated patients. No significant malignant arrhythmias were detected in patients treated with istaroxime on Holter monitoring. CONCLUSIONS: In this small study, istaroxime doses of up to 1.0 µg/kg/min for up to 60 hours were associated with improvements in SBP, CO and reductions in wedge pressure and heart rate without increases in arrhythmias.
2. Percutaneous Transcatheter Edge-to-Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Reconstructed Time-to-Event Data.
Across three randomized trials (n=1423), TEER reduced heart failure hospitalizations (RR 0.73) and cardiovascular mortality (RR 0.79), and improved quality of life (KCCQ +14.3 points) compared with OMT. Reconstructed time-to-event analyses confirmed a 34% reduction in HF hospitalization risk and a 2.9-month gain in HFH-free survival, with attenuation after 15 months.
Impact: Synthesizes randomized evidence demonstrating TEER’s benefits in functional MR beyond medical therapy, with robust time-to-event re-analysis. Supports patient selection and expectation-setting regarding durability.
Clinical Implications: For symptomatic FMR with persistent HF despite guideline-directed therapy, TEER reduces HF hospitalizations and CV mortality and improves quality of life. Clinicians should counsel patients on likely benefits within the first 12–18 months and monitor for attenuation.
Key Findings
- HF hospitalization reduced vs OMT (RR 0.73, 95% CI 0.58–0.92; p<0.01).
- Cardiovascular mortality reduced (RR 0.79, 95% CI 0.66–0.95; p=0.01); all-cause mortality not statistically significant (RR 0.80; p=0.07).
- KCCQ improved by 14.32 points (95% CI 10.85–17.80; p<0.01).
- Reconstructed survival: 34% lower HFH risk (HR 0.65–0.66) and 2.9-month longer HFH-free survival; attenuation beyond 15 months.
Methodological Strengths
- Systematic review and meta-analysis confined to RCTs with reconstructed individual-level time-to-event data.
- Multiple endpoints including HF hospitalization, CV mortality, and patient-reported outcomes (KCCQ).
Limitations
- Only three trials; heterogeneity in inclusion criteria and device generations may influence generalizability.
- All-cause mortality effect not statistically significant; attenuation of benefit beyond 15 months suggests need for long-term data.
Future Directions: Longer-term RCT follow-up and device iteration studies; stratified analyses by proportionate/disproportionate MR and RV function; cost-effectiveness over multi-year horizons.
BACKGROUND: Mitral transcatheter edge-to-edge repair (TEER) is approved for patients with severe functional mitral regurgitation (FMR) beyond optimal medical therapy (OMT). AIMS: We aimed to assess TEER's efficacy beyond OMT in patients with severe FMR. METHODS: A systematic review and meta-analysis were conducted, including randomized controlled trials from PubMed, Cochrane, Scopus, and EMBASE up to September 2024. PRIMARY OUTCOME: heart failure hospitalization (HFH); secondary outcomes: cardiovascular (CV) mortality, all-cause mortality, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. Time-to-event data from Kaplan-Meier curves were reconstructed for individual patient data. RESULTS: Three studies (1423 patients) were included. TEER significantly reduced HFH (RR 0.73, 95% CI 0.58-0.92, p < 0.01) and CV mortality (RR 0.79, 95% CI 0.66-0.95, p = 0.01), and improved KCCQ scores (mean difference 14.32, 95% CI 10.85-17.80, p < 0.01) compared to OMT. No significant difference was found for all-cause mortality (RR 0.80, 95% CI 0.63-1.02, p = 0.07). Prognostic meta-analysis showed a 34% reduced risk of HFH (HR 0.66, 95% CI 0.45-0.96, p = 0.03), but no effect on all-cause or CV mortality. Reconstructed Kaplan-Meier analysis confirmed a 34% reduced risk of HFH (HR 0.65, p < 0.001), with effect attenuation after 15 months in landmark analysis (HR 0.64, p = 0.07). RMST analysis showed a 2.9-month longer HFH-free survival with TEER (p < 0.01). CONCLUSION: In patients with FMR, TEER significantly reduces HFH, improves functional status, and lowers CV mortality at 24 months but does not significantly affect all-cause mortality. The device group experienced a modest, but significant, 2.9-month longer HFH-free survival compared to the control group. However, the reduction in HFH showed attenuation beyond 15 months.
3. Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): A prospective, randomized, mechanistic study.
In a single-center randomized, single-blind mechanistic trial (n=50), isotonic 0.9% NaCl infusion plus protocolized diuretics produced higher 24–48 h urine output and natriuresis than 5% glucose, with lower furosemide doses. Lithium fractional excretion was higher with NaCl, indicating reduced proximal tubular sodium reabsorption and sodium avidity.
Impact: Challenges a long-held paradigm by showing sodium/chloride supplementation can enhance decongestion when combined with diuretics in AHF. Provides mechanistic links via proximal tubular handling.
Clinical Implications: In monitored AHF decongestion, isotonic saline co-infusion may increase diuresis/natriuresis and reduce loop diuretic exposure. Patient selection and electrolyte management are essential; multicenter outcome studies are needed before routine adoption.
Key Findings
- Higher 48-hour cumulative urine output with NaCl vs glucose (9500 vs 7395 mL; p=0.001).
- Greater natriuresis over 48 hours with NaCl (p<0.05) and lower cumulative furosemide dose (220 vs 280 mg; p=0.02).
- Higher fractional excretion of lithium with NaCl (19.0% vs 14.7%; p=0.030), indicating reduced proximal tubular sodium reabsorption.
- Lower relative distal sodium reabsorption with NaCl (86.9% vs 91.5%; p<0.001).
Methodological Strengths
- Prospective randomized, single-blind design with predefined co-primary endpoints.
- Mechanistic readouts (fractional excretion of lithium) linking effects to proximal tubular physiology.
Limitations
- Single-center with small sample size; short-term surrogate endpoints without clinical outcomes.
- Electrolyte balance and safety signals beyond 48 hours not fully characterized.
Future Directions: Multicenter pragmatic trials testing saline co-infusion strategies on dyspnea relief, decongestion success, renal safety, and rehospitalization; phenotyping responders by renal sodium handling.
AIMS: We questioned the long-standing paradigm that sodium/chloride restriction is essential for effective decongestion in acute heart failure (AHF). This study compared the decongestive effects of two isotonic infusion strategies: 5% glucose (for intravascular volume repletion only) versus 0.9% NaCl (providing additional sodium/chloride supplementation), both added to protocolized diuretic therapy. METHODS AND RESULTS: This single-centre, prospective, randomized, single-blind study included patients with fluid overload who were randomized 1:1 to continuous infusions (83.3 ml/h) of either 0.9% NaCl or 5% glucose for 48 h. Co-primary endpoints included 24- and 48-h urine output, natriuresis within 48 h, and total furosemide dose up to 48 h. The NaCl group (n = 25) significantly outperformed glucose group (n = 25) in all co-primary endpoints: the median urine output was higher in the NaCl group versus glucose group at 24 and 48 h (cumulative during 48 h: 9500 vs. 7395 ml, p = 0.001), the NaCl group had higher natriuresis during 48 h of decongestion (p < 0.05), which was achieved with lower cumulative doses of furosemide (220 vs. 280 mg, p = 0.02). The fractional excretion of lithium was higher in the NaCl versus glucose group (19.0 ± 8.9% vs. 14.7 ± 9.6%, p = 0.030), indicating inhibited proximal tubular sodium reabsorption. There was no difference in absolute distal reabsorption, but relative distal sodium reabsorption in the NaCl group was lower (86.9 ± 12.3% vs. 91.5 ± 9.3%, p < 0.001). CONCLUSIONS: The infusion of NaCl compared to glucose added to diuretic therapy led to significantly higher diuresis, natriuresis, and lower loop diuretic use, driven by lower sodium avidity and inhibition of proximal tubular sodium reabsorption. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT05962255.